MetaCap

Gyre Therapeutics (GYRE) vs Rezolute (RZLT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Gyre Therapeutics (GYRE) has outperformed Rezolute (RZLT) over the past year, losing 44.2% versus a loss of 60.1%. Over five years, RZLT leads with a -26.9% price change compared with -77.5% for GYRE. Rezolute is the larger company by market cap ($465.6 million vs $460.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GYRE-44.24%RZLT-60.12%
+21%-35%-91%
Nov 21, 20251 yearNov 20, 2026
GYRE-78.58%RZLT-32.41%
+94%-1%-96%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GYRE versus RZLT key metrics
MetricGYRERZLT
Share price$4.21$3.92
Market cap$460.79M$465.58M
1-day change-6.86%-6.67%
YTD return-40.37%+66.10%
1-year return-44.24%-60.12%
5-year return-77.55%-26.87%
Forward P/E70.17—
EPS (TTM)$-0.31$-0.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$116.59M—
Revenue growth (YoY)+10.24%—
Net income (latest FY)$9.88M$-77.60M
Gross margin95.35%—
Operating margin9.85%—
Net margin8.47%—
52-week high$9.14$11.17
52-week low$3.97$1.07
Distance from 52-week high-53.94%-64.89%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+343.47%+175.51%
Average volume181.04K1.66M
Shares outstanding109.45M118.77M
Employees62563
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GYRE has outperformed RZLT by 15.9 percentage points over the past year.

About Gyre Therapeutics

GYRE stock →

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees

About Rezolute

RZLT stock →

Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.

Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees

GYRE vs RZLT FAQ

Which is bigger, Gyre Therapeutics or Rezolute?

Rezolute (RZLT) is larger, with a market capitalization of $465.58M compared with $460.79M for Gyre Therapeutics (GYRE).

Which stock has performed better over the past year, GYRE or RZLT?

GYRE returned -44.24% over the past 12 months, compared with -60.12% for RZLT (price return, excluding dividends). Past performance does not predict future results.

Are Gyre Therapeutics and Rezolute in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons